Clinical Trial Update: Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) [Phase 3]

View source ↗

Summary

Phase 3 trial update on safety, tolerability, and immunogenicity of an HPV vaccine in healthy girls aged 9 to 15; results completed with posted results in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papillomavirus Infections

Drugs mentioned

• HPV vaccine

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Papillomavirus Infections | Phase 3 | Status: COMPLETED | Results posted: 2009-04-14